PRT-060318
Based on 4 publication(s) in Google Scholar
PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.59%
- CAS. Nr.: 1194961-19-7
- Formel: C18H24N6O
- Molecular Weight:340.42
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Diversity Library
HY-L099
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) PRT-060318
More
Biologische Aktivität
PRT-060318 (PRT318) (0-3 µM, 15 min) completely inhibits Heparin-induced thrombocytopenia (HIT) immune complex-induced aggregation of both human and transgenic HIT mouse platelets[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6 mice treated with KKO (20 mg/kg, i.p.)[1]
-
Dosage:10 and 30 mg/kg
-
Administration:i.g., b.i.d. for 7 days
-
Result:Significantly inhibited platelet deposition without affecting bleeding time.
Markedly reduced HIT immune complex-induced thrombosis in the lungs.
Significantly reduced the thrombosis score compared to vehicle.
Chemical Information
-
CAS. Nr. 1194961-19-7
-
Appearance Solid
-
Molecular Weight 340.42
-
Formel C18H24N6O
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(C)=C3)N
-
Synonyms
PRT318
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Environ Pollut
Investigating the role and mechanism of methionine in different types of skeletal fluorosis based on Siglec-15 methylation. [Abstract]2026 Feb 1:390:127432. PMID: 41349947 -
FASEB J
Receptor-Dependent and -Independent Effects of Hemin on Platelet Plasma Membrane Disintegration. [Abstract]2026 Jan 31;40(2):e71463. PMID: 41524235 -
-
Lösungsmittel & Löslichkeit
H2O : 25 mg/mL (73.44 mM; Need ultrasonic)
DMSO : 10 mg/mL (29.38 mM; ultrasonic and warming and adjust pH to 3 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (73.44 mM); Clear solution; Need ultrasonic
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (406 KB)
- English - EN (406 KB)
- Français - FR (406 KB)
- Deutsch - DE (406 KB)
- Norwegian - NO (406 KB)
- Español - ES (406 KB)
- Swedish - SV (406 KB)
- Italian - IT (406 KB)
- Korean - KR (406 KB)
- Portuguese - PT (406 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Reilly MP, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011 Feb 17;117(7):2241-6. [Content Brief]
[2]. Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul;26(7):1576-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.9375 mL | 14.6877 mL | 29.3755 mL | 73.4387 mL |
| 5 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | 14.6877 mL | |
| 10 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL | 7.3439 mL | |
| 15 mM | 0.1958 mL | 0.9792 mL | 1.9584 mL | 4.8959 mL | |
| 20 mM | 0.1469 mL | 0.7344 mL | 1.4688 mL | 3.6719 mL | |
| 25 mM | 0.1175 mL | 0.5875 mL | 1.1750 mL | 2.9375 mL | |
| H2O | 30 mM | 0.0979 mL | 0.4896 mL | 0.9792 mL | 2.4480 mL |
| 40 mM | 0.0734 mL | 0.3672 mL | 0.7344 mL | 1.8360 mL | |
| 50 mM | 0.0588 mL | 0.2938 mL | 0.5875 mL | 1.4688 mL | |
| 60 mM | 0.0490 mL | 0.2448 mL | 0.4896 mL | 1.2240 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
PRT-060318 Related Classifications
HY-12974 Related Classifications
Powered by Bioz